Track Dyne Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Dyne Therapeutics, Inc. DYN · Stock Open Dyne Therapeutics, Inc. in new tab

17.16 USD
EPS
-3.62
P/B
3.45
ROE
-74.56
Beta
1.21
Target Price
34.33 USD
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
EPS-3.62
Book Value4.97
Price to Book3.45
Debt/Equity26.24
% Insiders0.503%
Estimates
Forward P/E-4.84
Forward EPS-3.55
Target Mean Price34.33

DCF valuation

Model fair value for Dyne Therapeutics, Inc. (DYN)
Result
Sign in to run the valuation for DYN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
15 analysts · consensus Strong buy · mean target 34.33 USD (low 10.00, high 50.00) · as of 16 Nov 2026
Low 10.00
Mean 34.33
High 50.00
Price 17.16
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Dyne Therapeutics, Inc. Logo Dyne Therapeutics, Inc. Analysis (DYN)

United States Health Care Official Website Stock

Is Dyne Therapeutics, Inc. a good investment? Dyne Therapeutics, Inc. (DYN) is currently trading at 17.16 USD. Market analysts have a consensus price target of 34.33 USD. This suggests a potential upside from current levels.

Earnings Schedule: Dyne Therapeutics, Inc. is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is -3.55.

Investor FAQ

Does Dyne Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Dyne Therapeutics, Inc.?

Dyne Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -3.62.

Company Profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
NMS (United States) DYN
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion